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Background: Chronic myeloid leukemia (CML) is driven by the expression of the BCR-ABL oncoprotein. STAT5 is a
BCR-ABL substrate and persistently activated by tyrosine phosphorylation in CML cells. Activated STAT5 (pSTAT5)
drives proliferation and survival of leukemic cells and contributes to initial transformation and maintenance of the
disease. In cytokine-induced STAT5 signaling, phosphorylation of STAT5A on Y694 leads to nuclear accumulation of
the transcription factor, followed by DNA-binding and gene induction. However, Src-family kinases (SFK) mediate
cytoplasmic retention of pSTAT5A leading to attenuated target gene expression and colony formation in CML cells.
Results: In this study we show that autophosphorylation of Y416 in the highly conserved activation loop of SFK
generates a potent recruitment site for the SH2 domain of STAT5A. Binding of the SH2 domain to the activation
loop is required for STAT5AY694 phosphorylation by SFK, but at the same time promotes the persistent cytoplasmic
localization of the transcription factor as found in BCR-ABL+ leukemia. As a consequence of the complex formation
between tyrosine-phosphorylated SFK and the SH2 domain of STAT5A, the dimerization of STAT5A is impaired. We
further demonstrate that constitutively active STAT5AS710F escapes from SFK-mediated cytoplasmic retention by
enhancing STAT5A dimer stability.
Conclusion: Our results reveal important structural aspects of cytoplasmic pSTAT5A found in myeloid leukemias
and will contribute to the understanding of STAT5A mediated cytoplasmic signaling.
Keywords: CML, STAT5, Src family kinases, DimerizationBackground
Signal transducer and activator of transcription (STAT)
proteins are latent transcription factors that transmit
signals from membrane-bound surface receptors to the
nucleus. STAT proteins regulate proliferation, differenti-
ation and apoptosis, involved in diverse biological pro-
cesses such as hematopoiesis, tissue remodeling, immune
responses and inflammation [1].
The STAT family is composed of seven members (STAT1,
STAT2, STAT3, STAT4, STAT5A/B and STAT6) that
share a structurally related and conserved domain archi-
tecture: The N-terminal multimerization domain, a coiled-
coil domain, followed by the DNA-binding domain (DB), a
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unless otherwise stated.and the transactivation domain (TA). In canonical Janus
kinase (JAK)/STAT signaling, phosphorylated tyrosine res-
idues in the cytoplasmic part of activated receptors serve
as docking sites for SH2 domain containing proteins in-
cluding STATs. Activation of STAT family members is me-
diated by the phosphorylation of a single conserved
tyrosine residue, which results in dimerization via recipro-
cal phosphotyrosine-SH2 domain interactions, subsequent
nuclear accumulation, DNA-binding and target gene ex-
pression [1].
STAT5 is of central importance for hematopoiesis in
health and disease. Lymphocyte development is regu-
lated by a variety of cytokines such as IL-2, IL-4, IL-7,
IL-9, IL-15 and IL-21, which activate the JAK3/STAT5
signaling pathway through common γ chain (γc) receptors
[2]. JAK2 and SFK orchestrate STAT5 signaling events
downstream of erythropoietin- (Epo), thrombopoietin-
(Tpo) and epidermal growth factor (EGF) receptors [3,4].ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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proteins, which share 93% identity at the amino acid level
with most of the differences located in the TA domain.
STAT5A knockout mice exhibit a defective mammary
gland development and impaired lactogenesis, whereas
STAT5B expression is required for sexual dimorphism of
body growth and liver gene expression [5,6]. Finally, gene
targeting of both STAT5A and STAT5B in mice results in
multiple hematopoietic defects involving the survival and
proliferation of lymphoid lineages [7]. Previous results ob-
tained from mice expressing N-terminally truncated forms
of STAT5A/B additionally implicated STAT5 signaling in
myeloid cell differentiation [8].
In contrast to physiological transient signaling, persist-
ent STAT5 activation is a hallmark of many hemato-
logical malignancies including myeloproliferative neoplasms
(MPNs) such as polycythemia vera (PV, JAK2V617F), essen-
tial thrombocythemia (ET, JAK2V617F), systemic mastocy-
tosis (SM, cKITD816V), acute myeloid leukemia (AML,
FLT3-ITD) and chronic myeloid leukemia (CML, BCR-
ABL) [3]. CML is a clonal myeloproliferative disorder, that
is characterized by the presence of the Philadelphia
chromosome t(9;22) leading to the expression of BCR-
ABL, an oncogenic fusion protein with constitutive tyro-
sine kinase activity [9]. Despite the activation of numerous
signaling pathways, STAT5 is mainly a BCR-ABL substrate
and is persistently phosphorylated in CML cells [10]. Acti-
vated STAT5 drives proliferation and survival of leukemic
cells and contributes to initial transformation and main-
tenance of the disease [7,11,12].
Mounting evidence suggests that STAT5A-mediated
prosurvival signaling emerges from the cytoplasmic com-
partment, based on a cooperative crosstalk with the PI3-
K/Akt signaling pathway. While mechanistic details of this
crosstalk remain elusive, constitutively active STAT5A
(STAT5AS710F) was found in a complex with Gab2,
which promotes the cytoplasmic localization of the per-
sistently phosphorylated transcription factor in myeloid
leukemias [13].
In addition, several reports suggest a role of SFK such
as Hck, Lyn and Fyn in mediating tyrosine kinase inhibi-
tor (TKI) resistance in CML cells [14-16]. Moreover,
Hck is frequently overexpressed in myeloid leukemias
and links STAT5 to BCR-ABL signaling [17,18]. We re-
cently showed that SFK promote the cytoplasmic locali-
zation of pSTAT5A in the presence of BCR-ABL
through a mechanism that involves the SH2 domain of
STAT5A. As a consequence, STAT5 mediated gene ex-
pression is permanently attenuated in CML cells [19].
However, a detailed understanding of the underlying
mechanism is still lacking.
In this study, we provide evidence that the STAT5A
SH2 domain tightly binds to the phosphorylated Y416 in
the activation loop of SFK, resulting in the cytoplasmiclocalization and an impaired dimerization of the tran-
scription factor. These processes are dominant over the
BCR-ABL induced nuclear accumulation of STAT5A
and therefore give a rational explanation for the cyto-
plasmic localization of STAT5A in a number of myeloid
leukemias.
Results
Binding of STAT5A to SFK is mediated by the SH2 domain
of STAT5A
In order to analyze STAT5A nucleocytoplasmic trans-
port dynamics, we evaluated the subcellular distribution
of fluorescently labeled STAT5A (Figure 1A) in an
erythropoietin (Epo) responsive HeLa cell line. In the ab-
sence of a hormone stimulus, STAT5A-eYFP appeared
almost equally distributed (nucleus/cytoplasm (n/c) ra-
tio: 1.2, SD: 0.2, n = 30), whereas Epo treatment resulted
in nuclear accumulation of the transcription factor (n/c
ratio: 3.8, SD: 2.1, n = 30, p < 0.0001), demonstrating that
STAT5A-eYFP imitates functional characteristics of un-
tagged STAT5A (Figure 1B + D).
We have previously shown that SFK mediate the cyto-
plasmic localization of STAT5A in BCR-ABL expressing
cells, a process that involves the SH2 domain of STAT5A
[19]. To confirm these observations we analyzed the sub-
cellular distribution of STAT5A-eYFP and STAT5AR618Q-
eYFP, which harbors an inactivating mutation in the SH2
domain, in the presence of vSrc-dsRed in HeLa T-REx
FRT cells (Figure 1C). Compared to the unstimulated cells
in Figure 1B, the constitutively active tyrosine kinase vSrc-
dsRed caused the cytoplasmic localization of STAT5A-
eYFP (upper panel, n/c ratio: 0.7, SD: 0.2, n = 30, p <
0.0001) but not STAT5AR618Q-eYFP (middle panel, n/c
ratio: 1.1, SD: 0.3, n = 30, p = 0.2018) (Figure 1C +D).
STAT3-eYFP has been reported to localize to the nuclear
compartment under these conditions and served as a posi-
tive control in this experiment (lower panel, n/c ratio: 4.4,
SD: 1.5, n = 30, p < 0.0001) (Figure 1C +D) [20].
To study the interaction of STAT5A and Src kinases, we
performed co-immunoprecipitation (Co-IP) experiments
in HeLa T-REx FRT cells. Co-expression of vSrc-dsRed
and STAT5A-eYFP resulted in a robust interaction of both
proteins and subsequent phosphorylation of STAT5AY694
by vSrc-dsRed (Figure 1E) which is in good agreement
with previously published data showing that STAT5A is a
direct substrate of Src kinases [21]. However, STAT5A-
eYFP appeared to be predominantly cytoplasmic under
these experimental settings (Figure 1C, upper right panel).
Co-precipitation of vSrc-dsRed with STAT5AR618Q-eYFP
was decreased compared to STAT5A-eYFP, indicating that
the SH2 domain participates in the interaction between
STAT5A and Src kinases. In line with this concept, the
phosphorylation of Y694 of STAT5AR618Q-eYFP was dras-
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Figure 1 The SH2 domain of STAT5A is required for efficient binding to Src kinases. (A) Domain structure of fluorescently labeled STAT5A-eYFP.
(B) Subcellular localization of STAT5A-eYFP in the absence or presence of Epo. HeLa T-REx HA-EpoR cells stably transfected with STAT5A-eYFP were
stimulated with 1 U/ml Epo for 30 min and the localization of STAT5A-eYFP was analyzed by confocal microscopy. Scale bars: 20 μm. (C) Subcellular
localization of STAT5A-eYFP (upper panel), STAT5AR618Q-eYFP (middle panel) and STAT3-eYFP (lower panel) was investigated in the presence of
vSrc-dsRed. HeLa T-REx vSrc-dsRed cells were treated with 5 ng/ml doxycycline and transfected with the indicated constructs and the distribution of
fluorescently labeled fusion proteins was analyzed after 24 h by confocal microscopy. Scale bars: 20 μm. (D) Quantification of the relative subcellular
distribution of eYFP-labeled STAT3 and STAT5A constructs in HeLa T-REx HA-EpoR cells stably expressing STAT5A-eYFP (B) and HeLa T-REx vSrc-dsRed
cells transfected with STAT5A-eYFP, STAT5AR618Q-eYFP or STAT3-eYFP (C). The expression of the HA-EpoR and vSrc-dsRed was induced with 5 ng/ml
doxycycline for 24 hours. Mean fluorescence intensities (MFI) of the cytoplasm and nucleus were determined using the Zen 2012 software and changes
in the ratio between the compartments were plotted. The data shown are means ± SD of n = 30 cells and were statistically evaluated by Student’s
t-test. ***p < 0.0005. n.s. = not significant. (E + F) HeLa T-REx FRT cells were co-transfected with plasmids coding for STAT5A-eYFP or STAT5AR618Q-eYFP
and vSrc-dsRed or Hck-dsRed. Fluorescently labeled STAT5 was immunoprecipitated from cell lysates using a GFP antibody and analyzed by
immunoblotting for the presence of vSrc-dsRed or Hck-dsRed 24 h after transfection. The expression and phosphorylation of STAT5A and vSrc/Hck
proteins was analyzed in the whole cellular lysates (WCL) using antibodies against pY416-Src, Src, Hck, pY694/699-STAT5A/B and GFP.
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negative feedback regulation, we additionally examined
the interaction between STAT5A and Hck. Co-IP experi-
ments revealed that Hck-dsRed interacted much stronger
with STAT5A-eYFP compared to STAT5AR618Q-eYFP.
Consistently, the Hck mediated tyrosine phosphorylation
of STAT5AY694 was strictly dependent on a functional
SH2 domain of STAT5A (Figure 1F) [21]. Therefore, we
speculated that STAT5A binds tightly to a phosphorylated
tyrosine motif of Src kinases in a SH2 domain dependent
fashion and thus fails to localize to the nucleus.
STAT5A binds to phosphorylated Y416 in the activation
loop of Src kinases
Having shown that the SH2 domain is involved in the
interaction with SFK and is required for STAT5AY694
phosphorylation, we analyzed Src kinase tyrosine to
phenylalanine mutants to identify the phosphorylation
site that facilitates STAT5A recruitment (Figure 2A).
Co-expression experiments revealed that in contrast to
kinase activity affecting mutations such as K295N in the
ATP-binding pocket and Y416F in the activation loop,
mutations of critical residues in the SH3 (W118A) and
SH2 (R175L) domains of vSrc-dsRed had no impact on
STAT5AY694 phosphorylation, showing that these domains
do not contribute to substrate recognition (Figure 2A + B).
Notably, the Y416F mutant of vSrc-dsRed displayed a
markedly reduced capability to activate STAT5A, which
we attributed to the attenuated kinase activity that has
been reported for this construct [22].
We subsequently screened the amino acid sequence of
vSrc for tyrosine residues that could serve as potential
binding sites for the SH2 domain of STAT5A. Six tyro-
sine residues were included in the analysis, which are
putatively surface exposed in the structure of cSrc (PDB:
2SRC) or have been described to be phosphorylated
(Figure 2A) [23,24]. With the exception of kinase activity
impairing mutations (K295N, Y416F), we observed equal
STAT5AY694 phosphorylation levels independent of theSrc kinase mutant used in this experiment (Figure 2C).
Accordingly, all tested Y to F mutants of vSrc-dsRed but
not kinase-dead vSrcK295N-dsRed induced a significant
redistribution of pSTAT5A from the nuclear to the cyto-
plasmic compartment with vSrcY416F-dsRed exhibiting
the lowest capacity (n/c ratio: 1.0, SD: 0.2, n = 10, p =
0.0382) compared to non-transfected cells (n/c ratio: 1.2,
SD: 0.2, n = 10) (Figure 2D + E).
Based on these results, we concluded that the kinase
activity of Src is critical for promoting a constitutive
cytoplasmic localization of pSTAT5A and hypothesized
that the phosphorylation of Y416 in the activation loop of
SFK not only regulates kinase activity, but in addition gen-
erates a recruitment site for the STAT5A SH2 domain.
To support this idea, we studied the interaction be-
tween STAT5A-eYFP and two kinase activity impairing
vSrc-dsRed mutants. These mutants are characterized by
either the absence (Y416F) or a drastically reduced
(K295N) phosphorylation of Y416 in the activation loop
(Figure 2F). While STAT5A-eYFP formed a robust com-
plex with vSrc-dsRed, the interaction with kinase dead
vSrcK295N-dsRed and vSrcY416F-dsRed was drastically at-
tenuated. However, since the latter construct still caused
phosphorylation of STAT5AY694, we concluded that sub-
strate recognition is additionally mediated by an activation
loop independent mechanism (Figure 2F). Similar obser-
vations were made when we investigated the interaction of
STAT5A-eYFP with Hck-dsRed or the corresponding in-
activating and attenuating mutations HckK269N-dsRed and
HckY390F-dsRed, respectively (Figure 2G, see long expos-
ure for pY694-STAT5A-eYFP).
To further demonstrate that the SH2 domain of
STAT5A binds to the phosphorylated activation loop of
SFK, peptide precipitation assays were performed using
a non-phosphorylated peptide and a tyrosine phosphory-
lated peptide corresponding to the amino acid sequence
of the activation loop of the SFK members cSrc (vSrc),
Yes and Fyn (Figure 2A). WCL of HeLa T-REx FRT cells
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Figure 2 STAT5A binds to the phosphorylated activation loop of SFK. (A) Domain structure of vSrc-dsRed. Selected amino acids are
highlighted. A multiple sequence alignment of the activation loop of SFK is shown. Autophosphorylation site is highlighted (red). (*) conserved
amino acids, (:) similar properties [51]. Bold characters highlight peptide sequence used for precipitation. (B + C) HeLa T-REx FRT cells stably
expressing STAT5A-eYFP were transfected with the indicated vSrc-dsRed variants. Phosphorylation was analyzed 24 h after transfection using
antibodies against pY416-Src, Src, pY694/699-STAT5A/B and STAT5A. CTRL = untransfected cells. (D) Quantification of relative subcellular distribution
of STAT5A in HeLa T-REx FRT stably expressing STAT5A-eYFP and the indicated vSrc-dsRed mutants. Mean fluorescence intensity (MFI) of
eYFP-fluorescence in the cytoplasm and nucleus were determined using the Zen 2012 software and changes in the ratio between the compartments
were plotted. Data show means ± SD of n = 10 cells and were statistically evaluated by Student’s t-test. ***p < 0.0005, **p < 0.005, *p < 0.05, n.s. = not
significant. (E) HeLa T-REx FRT cells stably expressing STAT5A-eYFP were transfected with vSrcK295N-dsRed or vSrcY416F-dsRed. Subcellular distribution of
STAT5A-eYFP was analyzed 24 h after transfection by confocal microscopy. Scale bars: 20 μm. (F + G) HeLa T-REx FRT cells were co-transfected with
plasmids coding for vSrc-dsRed (Hck-dsRed), vSrcK295N-dsRed (HckK269N-dsRed) or vSrcY416F-dsRed (HckY390F-dsRed) and STAT5A-eYFP. STAT5-eYFP was
immunoprecipitated from cell lysates using a GFP antibody and analyzed by immunoblotting for the presence of vSrc-dsRed (Hck-dsRed) 24 h after
transfection. Expression and phosphorylation of STAT5A and vSrc proteins was analyzed in the WCL using antibodies against pY416-Src, Src, Hck,
pY694/699-STAT5A/B and GFP. (s) short exposure, (l) long exposure. (H) HeLa T-REx FRT cells expressing STAT5A-eYFP or STAT5AR618Q-eYFP were lysed
and incubated with a Src-peptide containing tyrosine- or phosphotyrosine 416. Precipitates and WCL were analyzed by immunoblotting using a
GFP-specific antibody.
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coupled to avidin-agarose beads. Immunoblot analysis of
the peptide precipitates revealed that STAT5A-eYFP, but
not STAT5AR618Q-eYFP could be successfully precipi-
tated with the phosphorylated Src-peptide. Binding to
the non-phosphorylated peptide appeared comparable to
background levels (Figure 2H).
Cytoplasmic retention of STAT5A in BCR-ABL positive cells
is mediated by the phosphorylated activation loop of SFK
We have previously shown that the SFK mediated
cytoplasmic retention of STAT5A is dominant over
BCR-ABL driven nuclear accumulation [19]. Here, we
investigated the role of the phosphorylated tyrosine resi-
due 416 in the activation loop of SFK for the cytoplas-
mic localization of STAT5A in BCR-ABL expressing
cells. Therefore, HeLa T-REx BCR-ABL cells were gener-
ated that express the oncogenic tyrosine kinase upon
doxycycline treatment.
In untreated cells STAT5A-eYFP appeared equally dis-
tributed (Figure 3A, upper panel), while the expression
of BCR-ABL resulted in the nuclear accumulation of
STAT5A-eYFP (Figure 3A, lower panel). In support of
our previous results, STAT5A-eYFP failed to accumulate
in the nuclear compartment of BCR-ABL positive cells
co-expressing vSrc-dsRed (Figure 3B, upper panel).
Interestingly, neither kinase dead vSrcK295N-dsRed (mid-
dle panel) nor vSrcY416F-dsRed (lower panel) was capable
of preventing the nuclear accumulation of STAT5A-
eYFP in these cells. Consistently, the co-expression of
BCR-ABL and kinase dead vSrcK295N-dsRed did not alter
the phosphorylation status of Y416, demonstrating that
the activation loop of Src kinases is not phosphorylated
by BCR-ABL (Figure 3C).
Taken together these results reveal that the cytoplas-
mic retention of pSTAT5A is primarily a consequence of
the kinase-substrate interaction, mediated through bindingof the phosphotyrosine residue in the activation loop of
SFK to the SH2 domain of STAT5A.
Cytoplasmic recruitment of STAT5A by activated SFK is
associated with defective dimerization
Our results so far indicated that the SH2 domain of
STAT5A binds to the phosphorylated Y416 in the activa-
tion loop of Src kinases. This interaction ultimately in-
terferes with STAT5A nuclear accumulation. Hence, we
wondered whether the interaction also impairs STAT5A
dimerization.
In order to compare STAT5A dimerization downstream
of erythropoietin receptors (EpoR) and Src kinases, we
expressed STAT5A-FLAG in doxycycline treated HeLa
T-REx HA-EpoR and HeLa T-REx vSrc-dsRed cells,
which were stably transfected with STAT5A-eYFP. EpoR
expressing cells were either treated with Epo to induce
STAT5A activation or were left untreated (Figure 4A,
lanes 1–2). Co-IP experiments revealed that STAT5A-
FLAG and STAT5A-eYFP formed dimers in stimulated
cells. We did not observe the formation of non-
phosphorylated preformed dimers, which has been de-
scribed for STAT3 [25-27]. Surprisingly, Src mediated
phosphorylation of STAT5A resulted in a reduced
dimerization compared to Epo stimulation, which could
not be attributed to expression or phosphorylation levels
of STAT5A (Figure 4A, lanes 2 + 4).
To support these findings we repeated the previous ex-
periment under native conditions. Dimers were separated
from monomers using blue native polyacrylamide gel
electrophoresis and only fluorescent proteins were de-
tected by fluorescence scanning of the gel. Dimerization of
STAT5A-eYFP was efficiently induced by Epo stimulation
and accompanied by a simultaneous loss of STAT5A
monomers (Figure 4B, lanes 1–2). Subsequent analysis of
the corresponding WCL revealed that STAT5A was phos-
phorylated at tyrosine 694 in response to Epo. In order to
AB
C
Figure 3 SFK-mediated cytoplasmic localization of STAT5A is dominant over BCR-ABL induced nuclear accumulation. (A) HeLa T-REx
BCR-ABL cells were transiently transfected with STAT5A-eYFP and either treated with 5 ng/ml doxycycline for 24 h to induce BCR-ABL expression
(lower panel) or left untreated (upper panel). Fixation was performed with methanol. Fixed cells were stained for BCR-ABL using a cABL-specific
primary antibody and a secondary antibody conjugated to Alexa Fluor-405. The subcellular distribution of STAT5A-eYFP was analyzed by confocal
microscopy. Scale bars: 20 μm. (B) The subcellular distribution of STAT5A-eYFP was investigated in the presence of vSrc-dsRed (upper panel),
vSrcK295N-dsRed (middle panel) or vSrcY416F-dsRed (lower panel) in HeLa T-REx BCR-ABL cells that were treated with 5 ng/ml doxycycline for 24 h.
Fixation was performed with methanol. Fixed cells were stained for BCR-ABL using an Abl-specific primary antibody and a secondary antibody
conjugated to Alexa Fluor-405. Scale bars: 20 μm. (C) HeLa T-REx BCR-ABL cells were co-transfected with vSrc-dsRed, or the respective kinase
activity affecting mutants vSrcK295N-dsRed or vSrcY416F-dsRed and STAT5A-eYFP. The cells were either treated with 5 ng/ml doxycycline for 24 h
(lanes 1–3) to induce the expression of BCR-ABL or left untreated (lane 4). Protein expression and phosphorylation in the cellular extracts was
investigated by immunoblotting with antibodies against pY412-cABL, cABL, pY694/699-STAT5A/B, STAT5A, pY416-Src and Src. α-Tubulin served as a
loading control.
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tion of STAT5A-eYFP, the transcription factor was stably
expressed in doxycycline treated HeLa T-REx vSrc-dsRed
cells. Interestingly, STAT5A-eYFP dimerization was dras-
tically decreased in response to vSrc-dsRed expression
compared to Epo stimulated cells, while STAT5A expres-
sion and phosphorylation levels remained comparable
(Figure 4B, lanes 2 + 4). Moreover, we were able to rescueSrc mediated STAT5A dimerization by using a constitu-
tively active STAT5A variant harboring a serine to phenyl-
alanine mutation in the TA domain at position 710
(Figure 4B, lane 6) [28]. The mechanism rendering
STAT5AS710F constitutively active remains unclear but
since the observed effect on STAT5AS710F dimerization
could not be attributed to increased expression or phos-
phorylation levels of this mutant, we speculate that F710
AC
B
Figure 4 Binding of STAT5A to Src kinases interferes with dimerization. (A) HeLa T-REx HA-EpoR cells stably expressing STAT5A-eYFP were
transfected with STAT5A-FLAG. The cells were treated with 5 ng/ml doxyxcyline for 24 h to induce the expression of the HA-tagged EpoR and
stimulated with 5 U/ml Epo for 30 minutes or left untreated. HeLa T-REx vSrc-dsRed cells stably expressing STAT5A-eYFP were transfected with
STAT5A-FLAG. The expression of vSrc-dsRed was induced for 8 h with 5 ng/ml doxycycline or the cells were left untreated. STAT5A-eYFP was
immunoprecipitated from cell lysates using a GFP antibody and analyzed by immunoblotting for the presence of STAT5A-FLAG. The expression
and phosphorylation of STAT5A-eYFP and STAT5A-FLAG was analyzed in the WCL using antibodies against pY694/699-STAT5A/B, GFP and the
FLAG-tag. (B) HeLa T-REx HA-EpoR cells stably expressing STAT5A-eYFP were treated with 5 ng/ml doxyxcyline for 24 h to induce the expression
of the human EpoR and stimulated with 5 U/ml Epo for 30 minutes or left untreated. HeLa T-REx vSrc-dsRed cells stably expressing STAT5A-eYFP
or a STAT5AS710F-eYFP were treated with 5 ng/ml doxyxcline for 8 h or the cells were left untreated. Cellular extracts were prepared under native
conditions and STAT5A-eYFP dimers were separated from monomers by blue native PAGE electrophoresis (NP). STAT5A-eYFP dimer complexes
were measured by the detection of the eYFP fluorescence. The cellular extracts were subjected to immunoblotting using antibodies against
pY694/699-STAT5A/B, STAT5A, Src and the HA-tag of the EpoR. (C) Confocal microscopy analysis of HeLa T-REx FRT cells co-expressing vSrc-dsRed
together with STAT5AS710F-eYFP (upper panel), a serine phosphorylation mimicking mutant STAT5AS710D-eYFP (middle panel) or a serine
phosphorylation deficient mutant STAT5AS710A-eYFP (lower panel). Methanol fixation was performed 24 h after transfection. Scale bars: 20 μm.
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STAT5AS710F homodimers accumulate in the nucleus
over time (Figure 4B, lanes 4 + 6).
These results are substantiated by the fact that
STAT5AS710F-eYFP escaped from the cytoplasmic reten-
tion and predominantly localized to the nucleus of HeLa
T-REx FRT cells expressing vSrc-dsRed (Figure 4C,upper panel). To demonstrate that dimer stabilization in
STAT5AS710F critically depends on F710 and is not a
consequence of lacking S710 phosphorylation, this resi-
due was either mutated to aspartic acid (STAT5AS710D)
to mimic a constitutive serine phosphorylation or to ala-
nine (STAT5AS710A) to prevent serine phosphorylation.
The subcellular distribution of these mutants was analyzed
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confocal microscopy. In contrast to STAT5AS710F-eYFP,
STAT5AS710D-eYFP and STAT5AS710A-eYFP predomin-
antly resided in the cytoplasm of vSrc-dsRed expressing
cells, suggesting that the hydrophobic properties of phe-
nylalanine at this position are of importance for the dimer
stabilization of STAT5AS710F.
Conclusively, our results indicate that binding of the
STAT5A SH2 domain to the phosphorylated activation
loop of SFK leads to a redistribution of the activated
transcription factor from the nucleus to the cytoplasm,
which is accompanied by impaired STAT5A dimer for-
mation (Figure 5).
Discussion
STAT5 signaling is implicated in proliferation, survival and
myeloid differentiation of hematopoietic cells. Aberrant
STAT5 activity is linked to the expression of dysregulated
upstream tyrosine kinases such as BCR-ABL, JAK2V617F,
FLT3-ITD or cKITD816V and represents a hallmark in a
variety of hematological malignancies including myelopro-
liferative neoplasias (MPNs) [29].
In CML, STAT5 represents a key signaling node since
pSTAT5 is essential for the proliferation and survival
of leukemic cells and contributes to both the initial
transformation and maintenance of the disease [11]. InFigure 5 Activated SFK interfere with dimerization and nuclear transl
Classical activation of the JAK2-STAT5A signaling pathway downstream of t
resulting in STAT5A dimerization, nuclear accumulation and finally target g
cytoplasmic localization of pSTAT5A is achieved (i) upon binding to the sca
Akt activation [35] and (ii) through binding of the STAT5A SH2 domain to t
with STAT5A dimerization and subsequent nuclear accumulation. Constitut
retention. Flashes indicate phosphorylation events.cytokine induced STAT5 signaling, phosphorylation of
a single tyrosine residue leads to dimerization and nu-
clear accumulation of the transcription factor, which
results in DNA binding and gene induction. However,
previous reports demonstrated that pSTAT5 predomin-
antly localizes to the cytoplasm of primary BCR-ABL
positive CML cells and cKITD816V positive neoplastic
mast cells [13,19,30]. Growing evidence supports the
idea that cytoplasmic pSTAT5 cooperates with the PI3-
K/Akt signaling pathway through the association with
the scaffolding adaptor Gab2 in order to maintain pro-
survival signaling [13,31-35].
Most recently, we identified Src family kinases (SFK)
to be involved in mediating the cytoplasmic retention of
pSTAT5A in BCR-ABL expressing cells, a process that
involves the SH2 domain of STAT5A. As a consequence,
STAT5A target gene expression was shown to be attenu-
ated, which could be rescued through the specific inhib-
ition of SFK [19]. Furthermore, it has been shown that
Src kinases phosphorylate STAT5A in in-vitro kinase as-
says, providing strong evidence for a direct interaction,
which is further substantiated by the co-localization of
pSTAT5 with constitutively active Hck in podosomes
[21,36].
However, the role of the STAT5A SH2 domain in this
context is still unresolved. In order to clarify theocation of pSTAT5A in BCR-ABL expressing cells. Left scheme:
he EpoR. Right scheme: BCR-ABL directly phosphorylates STAT5AY694
ene expression [10]. In the presence of BCR-ABL, a predominantly
ffolding adaptor Gab2 resulting in pro-survival signaling through PI3K/
he phosphorylated activation loop of SFK, a mechanism that interferes
ively active STAT5AS710F escapes the SFK-mediated cytoplasmic
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mic retention of STAT5A, we co-expressed STAT5A-
eYFP or STAT5AR618Q-eYFP with the SFK members
Hck-dsRed and vSrc-dsRed. We confirmed the observa-
tion that the SH2 domain of STAT5A is involved in the
formation of a stable complex with both SFK, which
contributes to the cytoplasmic localization of pSTAT5A.
Moreover, phosphorylation of STAT5AY694 by SFK re-
quires an intact STAT5A SH2 domain, which supports
the idea of an exceptional interaction between the kinase
and its substrate. Interestingly, the inactivating mutation
R618Q in the SH2 domain of STAT5A did not result in
a complete loss in binding to SFK, which indicates that
multiple domains contribute to the interaction.
In line with this concept, the SFK mediated activation
of the STAT family members STAT3 and STAT5B was
shown to be largely independent of a functional SH2 do-
main (data not shown) [19]. Consistently, nuclear functions
of STAT3 and STAT5B were reported to be important for
vSrc mediated cellular transformation [37-40].
Furthermore, the specific knockdown of STAT5B, but
not STAT5A, was shown to be associated with a loss of
CML cell proliferation. In the context of BCR-ABL sig-
naling, stress protection through the regulation of react-
ive oxygen species could be attributed to STAT5A
functions independent of its transcriptional activity, sug-
gesting a cytoplasmic role of pSTAT5A in this context
[41]. In contrast, other studies postulated a requirement
of the transcriptional activity of STAT5A for the regula-
tion of ROS, pointing towards a more nuclear function
of STAT5A in CML cells [42,43].
In order to further characterize the SFK/STAT5A pro-
tein interaction and its contribution to the cytoplasmic
localization of pSTAT5A, tyrosine to phenylalanine mu-
tations were introduced into vSrc-dsRed. Out of seven Y
to F mutations only the expression of vSrcY416F-dsRed,
which lacks the phosphorylation site in the activation
loop, resulted in a decreased STAT5AY694 phosphoryl-
ation. This observation is not surprising, since the Y416F
mutation negatively affects kinase activity. However, sub-
sequent interaction studies revealed that binding of
STAT5A to vSrcY416F-dsRed and vSrcK295N-dsRed is sig-
nificantly reduced compared to vSrc-dsRed, which corre-
lates with a substantial loss of Y416 phosphorylation and a
decreased capacity to induce the cytoplasmic localization
of STAT5A. In addition, STAT5A could be successfully
precipitated with a phosphorylated peptide corresponding
to the sequence of the activation loop of SFK in a SH2 do-
main dependent fashion. However, our experiments also
demonstrate that the binding of STAT5A to SFK is not
limited to phosphotyrosine-SH2 domain interactions,
which has also been shown for STAT5/Hck complexes in
BCR-ABL transformed haematopoietic cells and TEL-ABL
expressing Ba/F3 cells [18,44].Accordingly, our findings suggest that phosphorylation
of the activation loop, which is drastically reduced in
kinase dead vSrcK295N and absent in vSrcY416F, is re-
quired for the SFK induced cytoplasmic localization of
STAT5A in the presence of BCR-ABL. Taken into ac-
count that the SFK members Hck and Lyn are typically
expressed in myeloid cells and are constitutively acti-
vated by the p210 isoform of BCR-ABL, it is tempting to
speculate that activated SFK contribute to the persistent
cytoplasmic localization of pSTAT5A observed in pri-
mary CD34+ CML cells [13,17,19,45].
Having shown that SFK/STAT5A protein complexes are
stabilized by a phosphotyrosine-SH2 domain mediated
interaction, which is accompanied by a lack of nuclear ac-
cumulation, we wondered whether this interaction affects
STAT5A dimerization. Native gels revealed that the dimer
formation of STAT5A in response to activation through
SFK is significantly reduced compared to Epo stimulation,
despite equal phosphorylation levels. Interestingly, our un-
published data suggest that in response to SFK, STAT5A
is also phosphorylated at residues different from Y694,
which has also been reported for STAT5B [46]. Taken into
account that a cytoplasmic crosstalk between STAT5 and
p85, the regulatory subunit of PI3-K, has been postulated,
phosphorylated STAT5A in complex with SFK might
serve as a cytoplasmic scaffold for SH2 domain containing
proteins involved in this crosstalk [34,35].
The role of constitutive STAT5 activation and its con-
tribution to the development of blood malignancies has
been intensively investigated by the use of STAT5 acti-
vating mutations. A single point mutation in the transac-
tivation domain (S710F) renders STAT5A constitutively
active and promotes factor independent growth of Ba/F3
cells [28]. Despite the capability of STAT5AS710F but also
STAT5AS710A to rescue STAT5A−/− T cell proliferation,
only STAT5AS710F was shown to result in the induction
of leukemia upon expression in the bone marrow of wild-
type and STAT5−/− mice, demonstrating that the hydro-
phobic properties of phenylalanine are required for the
oncogenic potential of STAT5AS710F. However, a detailed
understanding of the mechanism rendering STAT5AS710F
constitutively active is lacking.
SFK failed to interfere with the dimerization of
STAT5AS710F-eYFP, which is in line with the observation
that STAT5AS710F-eYFP escapes from the SFK mediated
cytoplasmic retention and predominantly localizes to the
nuclear compartment. Phosphorylation of S710 is most
likely not involved in the regulation of the subcellular dis-
tribution of STAT5A, since mutants designed to impair
(STAT5AS710A) or to mimic (STAT5AS710D) serine phos-
phorylation could not rescue the SFK mediated block in
nuclear accumulation of STAT5A. Conceivably, our data
suggest that the oncogenic properties of STAT5AS710F are
a consequence of increased dimer stability that either
Fahrenkamp et al. Cell Communication and Signaling  (2015) 13:10 Page 11 of 14interferes with the deacetylation/sumoylation cycle, which
is involved in STAT5 inactivation, or impairs the recruitment
of STAT5 phosphatases such as SHP-2 and PTP1B [47-49].
Conclusions
Our findings identify Y416 in the conserved activation
loop of SFK as a recruitment site for the SH2 domain of
STAT5A. The phosphotyrosine-SH2 domain interaction
is required for the activation of STAT5A. At the same
time, this interaction promotes the cytoplasmic localiza-
tion of the transcription factor in BCR-ABL+ cells, which
is accompanied by an impaired dimerization. The onco-
genic STAT5AS710F mutant escapes from cytoplasmic
retention through SFK as a consequence of increased
dimer stability. These results reveal important structural
aspects of the cytoplasmic localization of pSTAT5A in
BCR-ABL expressing cells and will contribute to our un-
derstanding of STAT5A mediated cytoplasmic signaling.
Methods
Hormones and antibodies
Erythropoietin (Roche, Basel, Switzerland) was used at a
concentration of 1 or 5 U/ml. Anti-pY694/699-STAT5A/B
(#9351), anti-pY416-Src (#2101), anti-pY412-Abl (#2865),
anti-Hsp70 (#4872, Cell Signaling, Beverly, USA), anti-
STAT5A (clone #5073, rabbit polyclonal antiserum was
kindly provided by Richard Moriggl, Ludwig Boltzmann
Institute for Cancer Research (LBI-CR), Vienna, Austria),
anti-GFP (600-103-215, Rockland, Gilbertsville, USA), anti-
FLAG (F3165), anti-α-tubulin (T5168, Sigma, St. Louis,
USA), anti-GAPDH (sc-32233), anti-Abl (sc-131), anti-Hck
(sc-72), anti-cSrc (sc-19, Santa Cruz Biotechnology, Santa
Cruz, USA), anti-vSrc (MABS193, Millipore, Billerica,
MA, USA) and anti-HA (MMS-101R, Covance, Princeton,
New Jersey, USA) antibodies were used for immunoblot-
ting. The anti-pY416-Src antibody was used to detect
phosphorylated Y390 of Hck. Anti-rabbit, anti-mouse and
anti-goat antibodies conjugated to horseradish peroxidase
(HRP) were ordered from DAKO (Hamburg, Germany).
Plasmid constructs
The cDNA of murine STAT5A was either cloned into
the pcDNA3.1, pcDNA5/FRT/TO (Invitrogen, Paisley,
UK) or pLentiLox (Vector Core, University of Michigan,
USA) expression vectors and fused to the cDNA of the
enhanced yellow fluorescent protein (eYFP) or the
FLAG-tag (N’-DYKDDDDK-C’). The cDNA of vSrc and
human Hck (kindly provided by Isabelle Maridonneau-
Parini, Université Paul Sabatier, Toulouse, France) was
fused to monomeric dsRed and cloned into pcDNA3.1
or pcDNA5/FRT/TO expression vectors. The cDNA of
BCR-ABL (p210, kindly provided by Tim Brümmendorf,
Medizinische Klinik IV, RWTH Aachen, Germany) was
cloned into the pcDNA5/FRT/TO expression vector.The cDNA of the human erythropoietin receptor (EpoR)
was cloned into the pcDNA5/FRT/TO expression vector
and fused to the cDNA of the hemagglutinin tag (HA).
Fluorescent proteins and the FLAG-tag were fused to
the C-terminus of target proteins, whereas the HA-tag
was fused to the N-terminus of the human EpoR. Point
mutants of STAT5A, Hck and vSrc were generated with
the PCR based QuikChange XL Site-Directed Mutagenesis
Kit according to manufacturer’s instructions (Agilent
Technologies, Santa Clara, CA, USA).
Cell culture, transfection and inducible cell lines
HeLa T-REx (Invitrogen, Paisley, UK) cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM)/GlutaMAX
(Gibco, Paisley, UK). Transient transfection of HeLa
T-REx cells was performed using TransIT®-LT1 (Mirus,
Madison, USA) according to manufacturer’s instructions.
Stable transfection of HeLa T-REx cells for the inducible
expression of BCR-ABL, HA-EpoR, vSrc-dsRed and Hck-
dsRed were generated with the Flp-In system (Invitrogen,
Paisley, UK) using 250 μg/ml hygromycin B (PAA,
Austria) and 15 μg/ml blasticidin (Invivogen, Toulouse,
France) for selection. Non-inducible HeLa T-REx FRT
cells were maintained in DMEM medium supplemented
with 200 μg/ml Zeocin (Invivogen, Toulouse, France) and
15 μg/ml blasticidin. The expression of the gene of interest
was induced with 5 ng/ml doxycycline (Sigma, St. Louis,
USA) for 24 h or as indicated. All media were supple-
mented with 10% FCS (Lonza, Verviers, Belgium) and 25
U/ml penicillin/streptomycin (Lonza, Verviers, Belgium).
Cells were incubated at 37°C in a water-saturated atmos-
phere with 5% CO2.
Lentiviral mediated stable transduction
To achieve stable and constitutive expression of STAT5A
constructs in inducible HeLa T-REx cells, self-inactivating
lentiviral constructs were used according to the guidelines
of the RNAi consortium. Briefly, the cDNA of STAT5A-
eYFP and STAT5AS710F-eYFP were cloned into the lenti-
viral pLentiLox expression vector downstream of the
CMV promoter (Vector Core, University of Michigan,
USA). HEK293-T packaging cells were seeded on 6-cm
dishes on the first day to be 80-90% confluent at the time
of transfection. On the second day, HEK293-T cells were
transiently co-transfected with the lentiviral vector, psPAX2
(packaging plasmid) and pMD2.G (envelope plasmid).
Eighteen hours after transfection the culture medium was
replaced by high serum growth medium containing 30%
FCS. Viruses were harvested 24 and 48 hours after medium
exchange. For the infection of target cells, virus-containing
supernatant was supplemented with 8 μg/ml polybrene
(Sigma, St. Louis, USA) prior to incubation. For sorting by
fluorescence-activated cell sorter analysis (FACS), cells
were grown for 10 days and sorted by eYFP gating.
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immunoblotting
HeLa T-REx cells were washed with PBS (137 mM NaCl,
2.5 mM KCl, 8 mM Na2HPO4, 1.5 mM KH2PO4, ad-
justed to pH 7.4) once and lysed with RIPA lysis buffer
(50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA,
0,5% Nonidet P-40, 1 mM NaF, 15% glycerol) supple-
mented with phosphatase/protease inhibitors (1 mM
Na3VO4, 0.5 mM EDTA, 0.25 mM phenylmethylsulfo-
nylfluoride (PMSF), 5 μg/ml aprotinin, 2.5 μg/ml leupep-
tin) according to standard procedures. The proteins
were separated by SDS-PAGE and transferred to a PVDF
membrane with subsequent immunodectection using
specific antibodies. Primary and HRP-conjugated sec-
ondary antibodies were diluted in TBS-N buffer (20 mM
Tris–HCl, pH 7.5, 135 mM NaCl, 0.1% Nonidet P-40).
Membrane-bound antibody complexes were detected by
chemiluminescence (ECL, Millipore, Billerica, MA, USA).
Blue Native PAGE and detection of enhanced YFP
Dimerization of fluorescently eYFP-labeled STAT5A
constructs was analyzed in HeLa T-REx vSrc-dsRed and
HeLa T-REx HA-EpoR cells. Cell lysis was performed
under native conditions using the lysis buffer of the
NativePAGE™ Sample Prep Kit (Invitrogen, Paisley, UK)
supplemented with 2% digitonin (Sigma, St. Louis, USA).
The lysates were cleared by centrifugation and incubated
with Coomassie brilliant blue G-250 and separated over
night at 4°C using the NativePAGE™ Bis-Tris gel system
with a gradient polyacrylamide gel (4-16%) according to
manufacturer’s instructions. Dimerization of STAT5A-eYFP
was analyzed by the detection of the eYFP fluorescence
with a typhoon fluorescence scanner (GE Healthcare,
Germany) by excitation with a 488 nm laser line. The
emission was detected using a 515–555 nm bandpass
filter.
Peptide precipitation assay
HeLa T-REx FRT cells expressing STAT5A-eYFP or
STAT5AR618Q-eYFP were lysed with storage buffer
(150 mM NaCl, 50 mM Tris–HCl, pH 7.5, 0.1 mM
EDTA, 10% glycerol, 0.5% Nonidet P-40) supplemented
with phosphatase/protease inhibitors. Lysates were cleared
by ultracentrifugation (100.000 g, 30′, 4°C). Biotinylated
peptides corresponding to the activation loop sequence of
Src family kinases (N’-RLIEDNE(p)YTARQGAK-C’) were
synthesized with >95% purity (Genosphere Biotechnolo-
gies, Paris, France). 25 nmol of the peptides were
coupled to NeutrAvidin Agarose Resin (Thermo Scien-
tific, Pittsburgh, PA, USA) for 2 h at 4°C, washed twice
with storage buffer and incubated with 1 mg of the lysate
over night at 4°C. Peptide/protein complexes were washed
3 times with storage buffer for 10 minutes and the precipi-
tates were analyzed by SDS-PAGE and immunoblotting.Immunoprecipitation
HeLa T-REx cells were lysed with RIPA lysis buffer
(50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA,
0,5% Nonidet P-40, 1 mM NaF, 15% glycerol) supple-
mented with phosphatase/protease inhibitors and the ly-
sates were cleared by ultracentrifugation (100.000 g, 30′,
4°C). Protein G Sepharose (GE Healthcare, Dornstadt,
Germany) was coupled to 1 μg anti-GFP antibody for
16 h at 4°C, washed twice with RIPA buffer and subse-
quently incubated with 1 mg of lysates over night at 4°C.
Antibody/protein complexes were washed 3 times with
RIPA buffer for 10 minutes and precipitates were ana-
lyzed by SDS-PAGE and immunoblotting.Indirect immunofluorescence and confocal microscopy
HeLa T-REx cells expressing fluorescently labeled fusion
proteins were grown on glass cover slips. Methanol fix-
ation was performed at room temperature as has been
described previously [50]. Primary antibodies were di-
luted 1:100, secondary Alexa Fluor-405 conjugated anti-
bodies (Invitrogen, Paisley, UK) were diluted 1:1000 and
applied for 45 minutes. The cover slips were mounted
with ImmuMount (Thermo Scientific, Pittsburgh, PA).
Fluorescence images of adherent cells were generated
with a Zeiss LSM 710 confocal microscope (Zeiss, Jena,
Germany), using the Zeiss LD C-apochromat 40x/1.1
water objective. Images represent confocal slices of ap-
proximately 1 μm and were analyzed with the ZEN 2012
software (Zeiss, Jena, Germany).Quantification of the subcellular distribution of STAT5A
HeLa T-REx cells expressing STAT3-eYFP and STAT5A-
eYFP fusion constructs were fixed as described previ-
ously. Tilescan images (9 images, zoom 0.6) of adherent
cells were generated with a Zeiss LSM 710 confocal
microscope (Zeiss, Jena, Germany), using the Zeiss LD
C-apochromat 40x/1.1 water objective. Tilescan images
represent confocal slices of approximately 1 μm. Mean
fluorescent intensities (MFI) of the YFP fluorescence in
the cytoplasm and nucleus were calculated for double
transfected cells using the profile function of the ZEN
2012 software (Zeiss, Jena, Germany). Relative ratios of
nuclear versus cytoplasmic fusion proteins were plotted
using Graph Pad Prism 4 software and statistically evalu-
ated by Student’s t-test.
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